08:00 , Feb 14, 2011 |  BC Week In Review  |  Company News

Avecia, Nitto Denko deal

Nitto Denko acquired Avecia's Avecia Biotechnology Inc. subsidiary for an undisclosed sum. The subsidiary, through its OligoMedicines division, provides contract manufacturing services. Further details were not disclosed. Avecia Ltd. , Manchester, U.K.   Nitto Denko...
07:00 , Nov 1, 2010 |  BioCentury  |  Regulation

Biosimilar Fault Lines

The passage of the Patient Protection and Affordability Act seven months ago created a biosimilars pathway but left FDA a great deal of discretion to create the rules of the road. The battle over those...
08:00 , Dec 21, 2009 |  BC Week In Review  |  Company News

Avecia, Merck deal

Merck will acquire Avecia's Avecia Biologics Ltd. subsidiary, a contract manufacturing organization that specializes in microbial-derived biologics. Merck said the acquisition would expand its manufacturing capacity for biologics. Avecia's OligoMedicines business, located in Milford, Mass.,...
07:00 , Jun 23, 2008 |  BC Week In Review  |  Clinical News

BaroFeron: Phase I started

BaroFold began a double-blind, dose-escalation, Dutch Phase I trial in up to 60 volunteers. Avecia Biologics Ltd. (Manchester, U.K.) will manufacture the product for BaroFold. BaroFold Inc. , Boulder, Colo.   Product: BaroFeron   Business:...
01:17 , Apr 8, 2008 |  BC Extra  |  Politics & Policy

U.K. establishes life sciences marketing board

U.K. Trade & Investment, the U.K. government's international business development organization, established the U.K. LifeScience Marketing Strategy Implementation Board to promote the government's expertise in the biotechnology, pharmaceutical and healthcare sectors. The board's responsibilities will...
07:00 , Apr 7, 2008 |  BC Week In Review  |  Company News

Avecia Group plc, PharmAthene deal

PharmAthene completed its previously announced acquisition of Avecia's biodefense vaccines business for $10 million at closing, $7 million within 18 months of closing, and up to $23 million in milestones. Previous terms of the deal...
07:00 , Mar 24, 2008 |  BC Week In Review  |  Company News

Avecia Group plc, PharmAthene deal

Biodefense company PharmAthene will acquire all assets and IP related to Avecia's biodefense vaccines business for $10 million at closing, another $10 million within 12 months of closing, and up to $20 million in milestones....
01:19 , Mar 21, 2008 |  BC Extra  |  Company News

PharmAthene acquiring Avecia's biodefense vaccines

Biodefense company PharmAthene (AMEX:PIP) will acquire all assets and IP related to Avecia's biodefense vaccines business. The deal gives PharmAthene a second-generation recombinant protective antigen (rPA) anthrax vaccine that has completed Phase II testing; a...
07:00 , Oct 15, 2007 |  BC Week In Review  |  Company News

Avecia Biologics Ltd., BaroFold deal

Avecia will manufacture BaroFold's BaroFeron , an interferon (IFN) beta modified under high pressure to have low levels of soluble aggregates, for clinical testing. The compound is expected to start Phase I testing to treat...
07:00 , May 7, 2007 |  BC Week In Review  |  Company News

Avecia sales and marketing update

Avecia's Avecia Biologics unit launched its pAVEway expression system for microbial production of proteins. Avecia Ltd. , Manchester, U.K.   Business: Biomanufacturing  ...